{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T09:48:11Z","timestamp":1785836891012,"version":"3.56.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"},{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"}],"funder":[{"DOI":"10.13039\/501100008977","name":"Universit\u00e4t Ulm","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100008977","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nervenarzt"],"abstract":"<jats:title>Zusammenfassung<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Hintergrund<\/jats:title>\n                    <jats:p>Cannabidiol (CBD) hat in den letzten Jahren anhaltende allgemeine sowie medizinische und wissenschaftliche Aufmerksamkeit erlangt. Die Konsumpr\u00e4valenz von kommerziell erh\u00e4ltlichen CBD-haltige Pr\u00e4paraten (KCP) ist entsprechend hoch.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ziel der Arbeit<\/jats:title>\n                    <jats:p>\u00dcbersicht \u00fcber Nutzen und Risiken von KCP unter Beachtung einiger Aspekte, die CBD als pharmazeutischen Wirkstoff betreffen.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Material und Methoden<\/jats:title>\n                    <jats:p>Selektive Literaturrecherche in der Datenbank PubMeb.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ergebnisse<\/jats:title>\n                    <jats:p>Aktuell ist nur ein prim\u00e4r CBD-haltiges Medikament in Deutschland zugelassen (Epidyolex\u00ae). CBD weist eine gute Sicherheit und Vertr\u00e4glichkeit auf. Transaminasenerh\u00f6hungen, Sedierung, Appetitminderung, Diarrhoe, Schlafst\u00f6rungen, Infektionen und Gewichtsverlust sind m\u00f6gliche Nebenwirkungen. CBD moduliert das Endocannabinoidsystem und interagiert mit zahlreichen weiteren molekularen Zielen. CBD wird \u00fcber CYP2C19, CYP3A4 und UGT metaboliert. Das pharmakokinetisches Interaktionspotential von CBD ist nicht gut untersucht, theoretisch aber gro\u00df. Das Missbrauchspotential von CBD ist bei oraler Anwendung vernachl\u00e4ssigbar, sollte jedoch bei inhalativer und h\u00f6her dosierter Anwendung st\u00e4rker gepr\u00fcft werden. In Studien fand sich bei vielen KCP eine ausgepr\u00e4gte Diskrepanz zwischen angegebenem und tats\u00e4chlichem CBD-Gehalt; h\u00e4ufig konnte THC nachgewiesen werden. Es gibt keine die herstellerseitig typischerweise behaupteten gesundheitsbezogenen Vorteile von \u2264\u202f4,3\u202fmg oralem CBD\/kg\/d unterst\u00fctzende Evidenz, aber Hinweise auf relevante Hepatotoxizit\u00e4t bei \u2265\u202f4,3\u202fmg oralem CBD\/kg\/d.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Diskussion<\/jats:title>\n                    <jats:p>Es gibt keine belastbare Evidenz f\u00fcr gesundheitsbezogene Vorteile von KCP. Unter Beachtung erreichbarer Expositionen, der Produktm\u00e4ngel sowie der Sicherheitsbedenken der EFSA m\u00fcssen jedoch relevante Gesundheitsrisiken (v.\u202fa. Hepatotoxizit\u00e4t) bei der Anwendung von KCP angenommen werden.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00115-026-01998-9","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T09:35:05Z","timestamp":1785836105000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Psychiatrisch relevante Aspekte kommerziell erh\u00e4ltlicher Cannabidiol-haltiger Produkte","Psychiatric aspects of commercially available products containing cannabidiol"],"prefix":"10.1007","author":[{"given":"Maximilian","family":"Gahr","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,4]]},"reference":[{"key":"1998_CR1","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1021\/acs.jnatprod.5b00949","volume":"79","author":"O Aizpurua-Olaizola","year":"2016","unstructured":"Aizpurua-Olaizola\u00a0O, Soydaner\u00a0U, Ozturk\u00a0E et\u00a0al (2016) Evolution of the Cannabinoid and Terpene Content during the Growth of Cannabis sativa Plants from Different Chemotypes. J\u00a0Nat Prod 79:324\u2013331","journal-title":"J Nat Prod"},{"key":"1998_CR2","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1111\/bcp.14973","volume":"88","author":"CA Arout","year":"2022","unstructured":"Arout\u00a0CA, Haney\u00a0M, Herrmann\u00a0ES et\u00a0al (2022) A placebo-controlled investigation of the analgesic effects, abuse liability, safety and tolerability of a range of oral cannabidiol doses in healthy humans. Br J Clin Pharmacol 88:347\u2013355","journal-title":"Br J Clin Pharmacol"},{"key":"1998_CR3","doi-asserted-by":"crossref","unstructured":"Atalay S, Jarocka-Karpowicz I, Skrzydlewska E (2019) Antioxidative and Anti-Inflammatory Properties of Cannabidiol. Antioxidants (Basel) 9","DOI":"10.3390\/antiox9010021"},{"key":"1998_CR4","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.drugalcdep.2016.11.030","volume":"172","author":"S Babalonis","year":"2017","unstructured":"Babalonis\u00a0S, Haney\u00a0M, Malcolm\u00a0RJ et\u00a0al (2017) Oral cannabidiol does not produce a signal for abuse liability in frequent marijuana smokers. Drug Alcohol Depend 172:9\u201313","journal-title":"Drug Alcohol Depend"},{"key":"1998_CR5","doi-asserted-by":"publisher","DOI":"10.1111\/acer.70212","volume":"50","author":"MP Bogenschutz","year":"2026","unstructured":"Bogenschutz\u00a0MP, Blessing\u00a0E, Dgheim\u00a0D et\u00a0al (2026) Effects of cannabidiol in alcohol use disorder patients with and without co-occurring post-traumatic stress disorder: Tolerability but no evidence for efficacy in two randomized proof-of-concept trials. Alcohol Clin Exp Res (Hoboken) 50:e70212","journal-title":"Alcohol Clin Exp Res (Hoboken)"},{"key":"1998_CR6","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.neuro.2019.08.002","volume":"74","author":"S Bonaccorso","year":"2019","unstructured":"Bonaccorso\u00a0S, Ricciardi\u00a0A, Zangani\u00a0C et\u00a0al (2019) Cannabidiol (CBD) use in psychiatric disorders: A systematic review. Neurotoxicology 74:282\u2013298","journal-title":"Neurotoxicology"},{"key":"1998_CR7","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s00213-020-05712-8","volume":"238","author":"SC Britch","year":"2021","unstructured":"Britch\u00a0SC, Babalonis\u00a0S, Walsh\u00a0SL (2021) Cannabidiol: pharmacology and therapeutic targets. Psychopharmacology (Berl) 238:9\u201328","journal-title":"Psychopharmacology (Berl)"},{"key":"1998_CR8","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1002\/jat.3831","volume":"40","author":"RK Carvalho","year":"2020","unstructured":"Carvalho\u00a0RK, Andersen\u00a0ML, Mazaro-Costa\u00a0R (2020) The effects of cannabidiol on male reproductive system: A literature review. J\u00a0Appl Toxicol 40:132\u2013150","journal-title":"J Appl Toxicol"},{"key":"1998_CR9","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1038\/s41386-020-0667-2","volume":"45","author":"E Chesney","year":"2020","unstructured":"Chesney\u00a0E, Oliver\u00a0D, Green\u00a0A et\u00a0al (2020) Adverse effects of cannabidiol: a systematic review and meta-analysis of randomized clinical trials. Neuropsychopharmacology 45:1799\u20131806","journal-title":"Neuropsychopharmacology"},{"key":"1998_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2023.121838","volume":"329","author":"MP Coelho","year":"2023","unstructured":"Coelho\u00a0MP, Duarte\u00a0P, Calado\u00a0M et\u00a0al (2023) The current role of cannabis and cannabinoids in health: A comprehensive review of their therapeutic potential. Life Sci 329:121838","journal-title":"Life Sci"},{"key":"1998_CR11","volume":"24","author":"E Panel on Nutrition NF","year":"2026","unstructured":"Panel on Nutrition NF\u00a0E, A\u00a0F, D\u00a0T et\u00a0al (2026) Update of the statement on safety of cannabidiol as a novel food. EFSA\u00a0J 24:e9862","journal-title":"EFSA J"},{"key":"1998_CR12","doi-asserted-by":"crossref","unstructured":"Efsa Panel on Nutrition NF, Food A, Turck\u00a0D et\u00a0al (2022) Statement on safety of cannabidiol as a novel food: data gaps and uncertainties. EFSA J 20:e07322","DOI":"10.2903\/j.efsa.2022.7322"},{"key":"1998_CR13","doi-asserted-by":"publisher","first-page":"8711","DOI":"10.1074\/jbc.M114.618447","volume":"290","author":"MW Elmes","year":"2015","unstructured":"Elmes\u00a0MW, Kaczocha\u00a0M, Berger\u00a0WT et\u00a0al (2015) Fatty acid-binding proteins (FABPs) are intracellular carriers for Delta9-tetrahydrocannabinol (THC) and cannabidiol (CBD). J\u00a0Biol Chem 290:8711\u20138721","journal-title":"J Biol Chem"},{"key":"1998_CR14","doi-asserted-by":"crossref","unstructured":"Engeli BE, Lachenmeier DW, Diel P et\u00a0al. (2025) Cannabidiol in Foods and Food Supplements: Evaluation of Health Risks and Health Claims. Nutrients\u00a017","DOI":"10.3390\/nu17030489"},{"key":"1998_CR15","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1093\/ijnp\/pyaa031","volume":"23","author":"S Ganesh","year":"2020","unstructured":"Ganesh\u00a0S, Cortes-Briones\u00a0J, Ranganathan\u00a0M et\u00a0al (2020) Psychosis-Relevant Effects of Intravenous Delta-9-Tetrahydrocannabinol: A Mega Analysis of Individual Participant-Data from Human Laboratory Studies. Int J Neuropsychopharmacol 23:559\u2013570","journal-title":"Int J Neuropsychopharmacol"},{"key":"1998_CR16","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1111\/epi.13852","volume":"58","author":"TE Gaston","year":"2017","unstructured":"Gaston\u00a0TE, Bebin\u00a0EM, Cutter\u00a0GR et\u00a0al (2017) Interactions between cannabidiol and commonly used antiepileptic drugs. Epilepsia 58:1586\u20131592","journal-title":"Epilepsia"},{"key":"1998_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-023-17142-0","volume":"23","author":"J Geppert","year":"2023","unstructured":"Geppert\u00a0J, Lietzow\u00a0J, Hessel-Pras\u00a0S et\u00a0al (2023) Usage and health perception of cannabidiol-containing products among the population in Germany: a descriptive study conducted in 2020 and 2021. BMC Public Health 23:2318","journal-title":"BMC Public Health"},{"key":"1998_CR18","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1007\/s00213-021-05801-2","volume":"239","author":"B Gunasekera","year":"2022","unstructured":"Gunasekera\u00a0B, Diederen\u00a0K, Bhattacharyya\u00a0S (2022) Cannabinoids, reward processing, and psychosis. Psychopharmacology (Berl) 239:1157\u20131177","journal-title":"Psychopharmacology (Berl)"},{"key":"1998_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2024.116049","volume":"339","author":"K Han","year":"2024","unstructured":"Han\u00a0K, Wang\u00a0JY, Wang\u00a0PY et\u00a0al (2024) Therapeutic potential of cannabidiol (CBD) in anxiety disorders: A systematic review and meta-analysis. Psychiatry Res 339:116049","journal-title":"Psychiatry Res"},{"key":"1998_CR20","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.euroneuro.2014.11.014","volume":"25","author":"C Hindocha","year":"2015","unstructured":"Hindocha\u00a0C, Freeman\u00a0TP, Schafer\u00a0G et\u00a0al (2015) Acute effects of delta-9-tetrahydrocannabinol, cannabidiol and their combination on facial emotion recognition: a randomised, double-blind, placebo-controlled study in cannabis users. Eur Neuropsychopharmacol 25:325\u2013334","journal-title":"Eur Neuropsychopharmacol"},{"key":"1998_CR21","doi-asserted-by":"crossref","unstructured":"Huestis MA (2005) Pharmacokinetics and metabolism of the plant cannabinoids, delta9-tetrahydrocannabinol, cannabidiol and cannabinol. Handb Exp Pharmacol:657-690","DOI":"10.1007\/3-540-26573-2_23"},{"key":"1998_CR22","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s13311-015-0377-3","volume":"12","author":"C Ibeas Bih","year":"2015","unstructured":"Ibeas Bih\u00a0C, Chen\u00a0T, Nunn\u00a0AV et\u00a0al (2015) Molecular Targets of Cannabidiol in Neurological Disorders. Neurotherapeutics 12:699\u2013730","journal-title":"Neurotherapeutics"},{"key":"1998_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2022.109522","volume":"237","author":"E Johnson","year":"2022","unstructured":"Johnson\u00a0E, Kilgore\u00a0M, Babalonis\u00a0S (2022) Cannabidiol (CBD) product contamination: Quantitative analysis of Delta(9)-tetrahydrocannabinol (Delta(9)-THC) concentrations found in commercially available CBD products. Drug Alcohol Depend 237:109522","journal-title":"Drug Alcohol Depend"},{"key":"1998_CR24","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1038\/s41386-025-02141-z","volume":"50","author":"AE Kirkland","year":"2025","unstructured":"Kirkland\u00a0AE, Browning\u00a0BD, Meredith\u00a0LR et\u00a0al (2025) The neural and psychophysiological effects of cannabidiol in youth with alcohol use disorder: A randomized controlled clinical trial. Neuropsychopharmacology 50:1482\u20131492","journal-title":"Neuropsychopharmacology"},{"key":"1998_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2021.114347","volume":"308","author":"AE Kirkland","year":"2022","unstructured":"Kirkland\u00a0AE, Fadus\u00a0MC, Gruber\u00a0SA et\u00a0al (2022) A scoping review of the use of cannabidiol in psychiatric disorders. Psychiatry Res 308:114347","journal-title":"Psychiatry Res"},{"key":"1998_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s13034-024-00846-5","volume":"18","author":"P Kock","year":"2024","unstructured":"Kock\u00a0P, Badek\u00a0A, Meyer\u00a0M et\u00a0al (2024) Cannabinoids for treating psychiatric disorders in youth: a systematic review of randomized controlled trials. Child Adolesc Psychiatry Ment Health 18:158","journal-title":"Child Adolesc Psychiatry Ment Health"},{"key":"1998_CR27","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.euroneuro.2022.04.003","volume":"59","author":"CM Kwee","year":"2022","unstructured":"Kwee\u00a0CM, Baas\u00a0JM, Van Der Flier\u00a0FE et\u00a0al (2022) Cannabidiol enhancement of exposure therapy in treatment refractory patients with social anxiety disorder and panic disorder with agoraphobia: A randomised controlled trial. Eur Neuropsychopharmacol 59:58\u201367","journal-title":"Eur Neuropsychopharmacol"},{"key":"1998_CR28","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.euroneuro.2023.04.001","volume":"72","author":"CMB Kwee","year":"2023","unstructured":"Kwee\u00a0CMB, Leen\u00a0NA, Van Der Kamp\u00a0RC et\u00a0al (2023) Anxiolytic effects of endocannabinoid enhancing compounds: A\u00a0systematic review and meta-analysis. Eur Neuropsychopharmacol 72:79\u201394","journal-title":"Eur Neuropsychopharmacol"},{"key":"1998_CR29","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.19931.1","volume":"8","author":"DW Lachenmeier","year":"2019","unstructured":"Lachenmeier\u00a0DW, Habel\u00a0S, Fischer\u00a0B et\u00a0al (2019) Are adverse effects of cannabidiol (CBD) products caused by tetrahydrocannabinol (THC) contamination? F1000Res 8:1394","journal-title":"F1000Res"},{"key":"1998_CR30","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1684\/epd.2019.1123","volume":"22","author":"CJ Landmark","year":"2020","unstructured":"Landmark\u00a0CJ, Brandl\u00a0U (2020) Pharmacology and drug interactions of cannabinoids. Epileptic Disord 22:16\u201322","journal-title":"Epileptic Disord"},{"key":"1998_CR31","doi-asserted-by":"publisher","first-page":"2944","DOI":"10.1111\/ajt.15398","volume":"19","author":"AD Leino","year":"2019","unstructured":"Leino\u00a0AD, Emoto\u00a0C, Fukuda\u00a0T et\u00a0al (2019) Evidence of a clinically significant drug-drug interaction between cannabidiol and tacrolimus. Am J Transplant 19:2944\u20132948","journal-title":"Am J Transplant"},{"key":"1998_CR32","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1089\/can.2019.0078","volume":"7","author":"JP Liebling","year":"2022","unstructured":"Liebling\u00a0JP, Clarkson\u00a0NJ, Gibbs\u00a0BW et\u00a0al (2022) An Analysis of Over-the-Counter Cannabidiol Products in the United Kingdom. Cannabis Cannabinoid Res 7:207\u2013213","journal-title":"Cannabis Cannabinoid Res"},{"key":"1998_CR33","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1080\/19440049.2024.2319270","volume":"41","author":"N Lindekamp","year":"2024","unstructured":"Lindekamp\u00a0N, Triesch\u00a0N, Rohn\u00a0S et\u00a0al (2024) Quantification of sixteen cannabinoids in hemp seed edible oils and the influence of thermal processing on cannabinoid contents and profiles. Food Addit Contam Part A Chem Anal Control Expo Risk Assess 41:550\u2013562","journal-title":"Food Addit Contam Part A Chem Anal Control Expo Risk Assess"},{"key":"1998_CR34","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1111\/bph.12944","volume":"172","author":"JM Mcpartland","year":"2015","unstructured":"Mcpartland\u00a0JM, Duncan\u00a0M, Di Marzo\u00a0V et\u00a0al (2015) Are cannabidiol and Delta(9) -tetrahydrocannabivarin negative modulators of the endocannabinoid system? A\u00a0systematic review. Br J Pharmacol 172:737\u2013753","journal-title":"Br J Pharmacol"},{"key":"1998_CR35","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1038\/sj.bjp.0706415","volume":"146","author":"R Mechoulam","year":"2005","unstructured":"Mechoulam\u00a0R (2005) Plant cannabinoids: a\u00a0neglected pharmacological treasure trove. Br J Pharmacol 146:913\u2013915","journal-title":"Br J Pharmacol"},{"key":"1998_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.01365","volume":"9","author":"SA Millar","year":"2018","unstructured":"Millar\u00a0SA, Stone\u00a0NL, Yates\u00a0AS et\u00a0al (2018) A Systematic Review on the Pharmacokinetics of Cannabidiol in Humans. Front Pharmacol 9:1365","journal-title":"Front Pharmacol"},{"key":"1998_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2021.108514","volume":"127","author":"OS Miller","year":"2022","unstructured":"Miller\u00a0OS, Elder\u00a0EJ Jr, Jones\u00a0KJ et\u00a0al (2022) Analysis of cannabidiol (CBD) and THC in nonprescription consumer products: Implications for patients and practitioners. Epilepsy Behav 127:108514","journal-title":"Epilepsy Behav"},{"key":"1998_CR38","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1055\/a-2256-0098","volume":"57","author":"KR Muller-Vahl","year":"2024","unstructured":"Muller-Vahl\u00a0KR (2024) Cannabinoids in the Treatment of Selected Mental Illnesses: Practical Approach and Overview of the Literature. Pharmacopsychiatry 57:104\u2013114","journal-title":"Pharmacopsychiatry"},{"key":"1998_CR39","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1177\/07067437231209650","volume":"69","author":"JV Pinto","year":"2024","unstructured":"Pinto\u00a0JV, Crippa\u00a0JaS, Cereser\u00a0KM et\u00a0al (2024) Cannabidiol as an Adjunctive Treatment for Acute Bipolar Depression: A Pilot Study: Le cannabidiol comme traitement d\u2019appoint de la depression bipolaire aigue : une etude pilote. Can J Psychiatry 69:242\u2013251","journal-title":"Can J Psychiatry"},{"key":"1998_CR40","doi-asserted-by":"publisher","first-page":"e25","DOI":"10.1016\/j.forsciint.2018.10.019","volume":"294","author":"JL Poklis","year":"2019","unstructured":"Poklis\u00a0JL, Mulder\u00a0HA, Peace\u00a0MR (2019) The unexpected identification of the cannabimimetic, 5F-ADB, and dextromethorphan in commercially available cannabidiol e\u2011liquids. Forensic Sci Int 294:e25\u2013e27","journal-title":"Forensic Sci Int"},{"key":"1998_CR41","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.yebeh.2018.07.027","volume":"88","author":"KA Schoedel","year":"2018","unstructured":"Schoedel\u00a0KA, Szeto\u00a0I, Setnik\u00a0B et\u00a0al (2018) Abuse potential assessment of cannabidiol (CBD) in recreational polydrug users: A randomized, double-blind, controlled trial. Epilepsy Behav 88:162\u2013171","journal-title":"Epilepsy Behav"},{"key":"1998_CR42","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s00406-019-00978-2","volume":"269","author":"N Solowij","year":"2019","unstructured":"Solowij\u00a0N, Broyd\u00a0S, Greenwood\u00a0LM et\u00a0al (2019) A randomised controlled trial of vaporised Delta(9)-tetrahydrocannabinol and cannabidiol alone and in combination in frequent and infrequent cannabis users: acute intoxication effects. Eur Arch Psychiatry Clin Neurosci 269:17\u201335","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"1998_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2020.107937","volume":"211","author":"TR Spindle","year":"2020","unstructured":"Spindle\u00a0TR, Cone\u00a0EJ, Goffi\u00a0E et\u00a0al (2020) Pharmacodynamic effects of vaporized and oral cannabidiol (CBD) and vaporized CBD-dominant cannabis in infrequent cannabis users. Drug Alcohol Depend 211:107937","journal-title":"Drug Alcohol Depend"},{"key":"1998_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2020.106938","volume":"104","author":"L Taylor","year":"2020","unstructured":"Taylor\u00a0L, Crockett\u00a0J, Tayo\u00a0B et\u00a0al (2020) Abrupt withdrawal of cannabidiol (CBD): A randomized trial. Epilepsy Behav 104:106938","journal-title":"Epilepsy Behav"},{"key":"1998_CR45","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1002\/cpdd.950","volume":"10","author":"C Thai","year":"2021","unstructured":"Thai\u00a0C, Tayo\u00a0B, Critchley\u00a0D (2021) A Phase 1 Open-Label, Fixed-Sequence Pharmacokinetic Drug Interaction Trial to Investigate the Effect of Cannabidiol on the CYP1A2 Probe Caffeine in Healthy Subjects. Clin Pharmacol Drug Dev 10:1279\u20131289","journal-title":"Clin Pharmacol Drug Dev"},{"key":"1998_CR46","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1111\/bph.14440","volume":"176","author":"M Tham","year":"2019","unstructured":"Tham\u00a0M, Yilmaz\u00a0O, Alaverdashvili\u00a0M et\u00a0al (2019) Allosteric and orthosteric pharmacology of cannabidiol and cannabidiol-dimethylheptyl at the type 1 and type 2 cannabinoid receptors. Br J Pharmacol 176:1455\u20131469","journal-title":"Br J Pharmacol"},{"key":"1998_CR47","doi-asserted-by":"publisher","DOI":"10.1186\/s13048-018-0478-9","volume":"12","author":"OS Walker","year":"2019","unstructured":"Walker\u00a0OS, Holloway\u00a0AC, Raha\u00a0S (2019) The role of the endocannabinoid system in female reproductive tissues. J\u00a0Ovarian Res 12:3","journal-title":"J Ovarian Res"},{"key":"1998_CR48","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/S2215-0366(26)00015-5","volume":"13","author":"J Wilson","year":"2026","unstructured":"Wilson\u00a0J, Dobson\u00a0O, Langcake\u00a0A et\u00a0al (2026) The efficacy and safety of cannabinoids for the treatment of mental disorders and substance use disorders: a\u00a0systematic review and meta-analysis. Lancet Psychiatry 13:304\u2013315","journal-title":"Lancet Psychiatry"},{"key":"1998_CR49","first-page":"485","volume":"56","author":"AW Zuardi","year":"1995","unstructured":"Zuardi\u00a0AW, Morais\u00a0SL, Guimaraes\u00a0FS et\u00a0al (1995) Antipsychotic effect of cannabidiol. J\u00a0Clin Psychiatry 56:485\u2013486","journal-title":"J Clin Psychiatry"},{"key":"1998_CR50","doi-asserted-by":"crossref","unstructured":"Zuardi AW, Shirakawa I, Finkelfarb E et\u00a0al. (1982) Action of cannabidiol on the anxiety and other effects produced by delta 9\u2011THC in normal subjects. Psychopharmacology (Berl) 76:245\u2013250","DOI":"10.1007\/BF00432554"}],"container-title":["Der Nervenarzt"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-026-01998-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00115-026-01998-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-026-01998-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T09:35:12Z","timestamp":1785836112000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00115-026-01998-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,4]]},"references-count":50,"alternative-id":["1998"],"URL":"https:\/\/doi.org\/10.1007\/s00115-026-01998-9","relation":{},"ISSN":["0028-2804","1433-0407"],"issn-type":[{"value":"0028-2804","type":"print"},{"value":"1433-0407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,4]]},"assertion":[{"value":"17 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.\u00a0Gahr gibt an, dass kein Interessenkonflikt besteht.","order":1,"name":"Ethics","label":"Interessenkonflikt","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}}]}}